Reslizumab - Teva Pharmaceuticals
Alternative Names: Anti-interleukin-5-monoclonal antibody-Celltech/Schering-Plough; CDP-835; CEP-38072; CINQAERO; CINQAIR; Cinquil; CTx-55700; DCP-835; SCH 55700; TRFK-5Latest Information Update: 06 Jun 2023
At a glance
- Originator Celltech R&D; Schering-Plough
- Developer Allergy and Asthma Clinical Research; Celltech R&D; Teva Pharmaceutical Industries
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma
- Phase III Sinusitis
- Phase II Churg-Strauss syndrome
- No development reported Oesophagitis
Most Recent Events
- 06 Feb 2023 Launched for Asthma in Austria, Greece, Belgium, Finland, Spain, Denmark, Sweden, Portugal, Czech Republic, Netherlands, Poland, Hungary, United Kingdom, Russia, Norway (IV) prior to February 2023
- 19 Feb 2021 Discontinued - Phase-III for Asthma (In adolescents, In the elderly, Treatment-experienced, In adults) in New Zealand, Poland, Belgium, Russia, Australia, Hungary, South Africa, Spain, Ukraine, Argentina, France, Germany, Czech Republic, Israel, Italy, Mexico, South Korea, Canada, Netherlands, Japan, Turkey, Romania, USA (SC) (Teva Pharmaceuticals pipeline, February 2021)
- 10 Feb 2021 National Jewish Health completes a phase II trial in Churg-Strauss syndrome in USA (IV) (NCT02947945)